Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Aida Madzak, Torben Bjerregaard Larsen, Deirdre Lane, Gregory Y H Lip, Peter Brønnum Nielsen

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

OBJECTIVE: Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists (VKAs). The aim of this study is to examine the efficacy and safety of NOACs compared with warfarin with composite end points in patients with atrial fibrillation.

METHODS: This semi-systematic review performed a study of Phase III randomized controlled trials comparing NOACs with vitamin K antagonists (VKAs) in patient with atrial fibrillation using composite end points (combination of various clinical events). The use of composite end points allowed for combining efficacy and safety outcomes, thereby comparing the differences between NOAC and warfarin therapy from a clinical perspective.

RESULTS: Treatment with NOAC compared with warfarin was associated with a significant reduction in the sum of stroke or non-CNS, systemic embolism and major bleeding (odds ratio 0.87; 95% CI: 0.82-0.91).

CONCLUSION: Generally, NOACs were associated with a more favorable efficacy and safety profile compared with warfarin with regard to composite end points.

Original languageEnglish
Pages (from-to)1155-1163
Number of pages9
JournalExpert review of cardiovascular therapy
Volume13
Issue number10
Early online date24 Sep 2015
DOIs
Publication statusPublished - Oct 2015

Keywords

  • atrial fibrillation
  • efficacy
  • non-vitamin K oral anticoagulants
  • safety
  • Stroke prevention
  • warfarin

Fingerprint

Dive into the research topics of 'Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this